This page shows what was measured, who it was measured in, and what that does not settle.
What Adenosine phosphate does in the body
Adenosine Injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
Adenosine causes cardiac vasodilation which increases cardiac blood flow. Adenosine is thought to exert its pharmacological effects through activation of purine receptors (cell-surface A 1 and A 2 adenosine receptors). Although the exact mechanism by which adenosine receptor activation relaxes vascular smooth muscle is not known, there is evidence to support both inhibition of the slow inward calcium current reducing calcium uptake, and activation of adenylate cyclase through A 2 receptors in smooth muscle cells. Adenosine may also lessen vascular tone by modulating sympathetic neurotransmission.
Why people take it. Adenosine Injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 415SHH325A · read 2026-08-29
The supplement label database classes it as non-nutrient/non-botanical, under the name Adenosine.
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 132 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) Interim Maintenance High-dose Methotrexate Backbone
✗ The study did not show it
Who was studied
NCT02883049
How many people
5949
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA Drugs@FDA · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
ClinicalTrials.gov · a recorded source, not a stored snapshot
Overall survival
✗ The study did not show it
Who was studied
NCT00454480
How many people
2000
Study design
Phase 2/Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA Drugs@FDA · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
ClinicalTrials.gov · a recorded source, not a stored snapshot
Remission rate
✗ The study did not show it
Who was studied
NCT00198991
How many people
1883
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA Drugs@FDA · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
ClinicalTrials.gov · a recorded source, not a stored snapshot
Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL
✗ The study did not show it
Who was studied
NCT01536405
How many people
1412
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA Drugs@FDA · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
ClinicalTrials.gov · a recorded source, not a stored snapshot
Event-free survival of ALL patients (EFS)
✗ The study did not show it
Who was studied
NCT03117751
How many people
790
Study design
Phase 2/Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA Drugs@FDA · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
ClinicalTrials.gov · a recorded source, not a stored snapshot
Safety and efficacy of clofarabine combined with pegaspargase (phase II)
✗ The study did not show it
Who was studied
NCT01228331
How many people
745
Study design
Phase 2/Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA Drugs@FDA · a recorded source, not a stored snapshot
Europe PMC · a recorded source, not a stored snapshot
ClinicalTrials.gov · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
No description of who was studied is recorded.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of adenosine in patients less than 18 years of age have not been established.”
US prescribing information · 23e5c868-944f-4cc8-887f-9a2dc811af92 · read 2026-08-30
On older people, the label states: “Clinical studies with adenosine did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently.”
US prescribing information · 23e5c868-944f-4cc8-887f-9a2dc811af92 · read 2026-08-30
On people who are pregnant, the label states: “Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women.”
US prescribing information · 23e5c868-944f-4cc8-887f-9a2dc811af92 · read 2026-08-30
On people who are breastfeeding, the label states: “It is not known whether adenosine is excreted in human milk.”
US prescribing information · 23e5c868-944f-4cc8-887f-9a2dc811af92 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Withdrawn
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No form or route is recorded.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S8.
No source is stored against this line.
What is in the pack
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing is recorded about product quality.
No source is stored against this line.
Where it is registered
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No register entry is recorded.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
The exact form studied is not recorded.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
100 published labels name it as an active ingredient. 53 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · aeb29f2c-d1e8-981d-e053-2a95a90a2047 · read 2026-08-29
Those labels are classed as human otc drug and human prescription drug.
US prescribing information · aeb29f2c-d1e8-981d-e053-2a95a90a2047 · read 2026-08-29
3766 marketed supplement labels list this ingredient, classed as mineral, other combinations, single vitamin and mineral and vitamin.
Those labels carry all other, nutrient and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
Adenosine is intravenous at 3 DOSAGE FORMS AND STRENGTHS Adenosine Injection, USP is supplied as 20 mL and 30 mL single-dose vials containing a sterile, nonpyrogenic, clear solution of adenosine 3 mg per mL., recorded as fda label in effect 2022-07-01 in the United States.
US prescribing information · 23e5c868-944f-4cc8-887f-9a2dc811af92 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine, withdrawn medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Adenosine phosphate studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Adenosine phosphate are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
415SHH325A
CAS registry number
61-19-8
PubChem compound
6083
ChEMBL
CHEMBL752
ChEBI
16027
WHO international nonproprietary name list entry
335
RxNorm concept
309
EMA substance identifier
100000087682
European Chemicals Agency number
200-500-0
DrugBank
DB00131
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S8.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
Withdrawn in United States, 1973, for "Not safe or effective for intended use as vasodilator, anti-inflammatory" (ChEMBL; Open Targets)
What is missing or unclear◇Read from sources, not yet reviewed
What to learn next
Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (7)
Q2
62 registered trials of Adenosine phosphate — at which phases?
Registered studies posting no result
48 of 62
62 registered studies of Adenosine phosphate: 15 na, 14 phase3, 13 phase2, 9 phase1, 8 phase4, 5 na or unstated, 3 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
268 with a PubMed record
Show the evidence
na
15
phase3
14
phase2
13
phase1
9
phase4
8
na or unstated
5
8 more recorded rows
early phase1
3
completed
38
recruiting
6
terminated
6
unknown
6
withdrawn
3
active not recruiting
2
suspended
1
recorded 2026-09-01 · last checked 2026-09-04
Q3
Approved in 1989, withdrawn in 1973: what happened to Adenosine phosphate in United States?
"Not safe or effective for intended use as vasodilator, anti-inflammatory"
"Not safe or effective for intended use as vasodilator, anti-inflammatory"
recorded 2026-06-24 · last checked 2026-09-04
Q4
9 of Adenosine phosphate's trials stopped: safety, futility/efficacy, funding/business, other?
safety (1), futility/efficacy (1), funding/business (3) and other (4): Adenosine phosphate's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Study was terminated because funding could not be secured"; 9 of 62 registered studies
Show the evidence
Trial
NCT00179010
terminated; "Study was terminated because funding could not be secured"
NCT00580905
terminated; "Not enough volunteer recruited before funding could be secured."
NCT00612521
terminated; "At half the sample size, the results were negative with no benefit demonstrated with adenosine."
NCT02608944
withdrawn; "MRI perfusion techniques development took longer than expected."
NCT02867878
terminated; "inability to recruiti a sufficient number of patients"
NCT03236311
terminated; "(Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.)"
3 further recorded trials
NCT03249272
terminated; "Sponsor withdrew funding"
NCT04588441
withdrawn; "Study never started due to need for additional preclinical work requested by FDA\>"
NCT05014061
withdrawn; "Never started"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Adenosine phosphate used Adenosine 12mg — over how long?
studies of Adenosine phosphate used the recorded amount. ClinicalTrials.gov · 2026-09-01
1 recorded entry; human; also "Adenosine 12mg"
Show the evidence
humanNCT03344679
Adenosine 12mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Which 26 trials of Adenosine phosphate posted no result?
Posted no result
26 of 26 completed trials
Registrations
NCT00712764, NCT00184821, NCT00208312, NCT00944294, NCT00208299 and NCT00944970, and 20 more
Completion dates
oldest 2005-04; newest 2021-10-30
Show the evidence
Trial
NCT00712764
2005-04
NCT00184821
2005-05
NCT00208312
2005-06
NCT00944294
2006-04
NCT00208299
2006-08
NCT00944970
2006-12
14 further recorded trials
NCT00881686
2008-12
NCT01148147
2010-08
NCT00590070
2011-09
NCT00693758
2011-09
NCT01123525
2011-09
NCT00923962
2012-01
NCT00781404
2012-07
NCT01809743
2013-10
NCT02184117
2015-05
NCT03327168
2016-06-30
NCT01939912
2016-09
NCT01690884
2017-01
NCT02092428
2017-03-01
NCT02462941
2017-07
Q7
At the median, Adenosine phosphate's trials enrolled 68 people — anything larger?
Median enrolment
68
Largest enrolment
1231
Registered trials counted
61
Q8
What do 11 spontaneous reports say about Adenosine phosphate — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Adenosine phosphate appears in spontaneous reports to regulators. Across the 1 most-reported reaction term, 11 reaction mentions were counted: drug hypersensitivity 11. FAERS via Open Targets · CHEMBL752 · 2026-06-24
Show the evidence
drug hypersensitivity
11
recorded 2026-06-24 · last checked 2026-09-04
Where it is registered
Where it’s registered
Withdrawn in United States, 1973, for "Not safe or effective for intended use as vasodilator, anti-inflammatory" (ChEMBL; Open Targets)
✗ required summary fields resolved: 3 required field(s) not terminal: Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 5 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.